Joaquim José Coutinho Ferreira


AuthID: R-000-7JF

Publicações a aguardar confirmação

501
TÍTULO: Eslicarbazepine acetate: a new option for the treatment of focal epilepsy
AUTORES: Joaquim Ferreira; Tiago Mestre;
PUBLICAÇÃO: 2009, FONTE: Expert Opinion on Investigational Drugs - Expert Opin. Investig. Drugs, VOLUME: 18, NÚMERO: 2
INDEXADO EM: CrossRef
NO MEU: ORCID
502
TÍTULO: Alternative therapics and Parkinson's disease in Portugal
AUTORES: Gouveia, LO; Noronha, A; Finisterra, M; Coelho, M; Rosa, MM; Sampaio, C; Ferreira, JJ;
PUBLICAÇÃO: 2009, FONTE: MOVEMENT DISORDERS, VOLUME: 24
INDEXADO EM: WOS
NO MEU: ORCID
503
TÍTULO: "Espresso coffee" for the treatment of excessive daytime sleepiness in Parkinson's disease: Results of four pilot n-of-one clinical trials
AUTORES: Ferreira, JJ; Correia Guedes, L; Freire, RA; Coelho, M; Rosa, MM; Rascol, O; Sampaio, C;
PUBLICAÇÃO: 2009, FONTE: MOVEMENT DISORDERS, VOLUME: 24
INDEXADO EM: WOS
NO MEU: ORCID
504
TÍTULO: A systematic review of the incidence of fatigue as an adverse event in placebo-controlled trials for Parkinson's disease
AUTORES: Ferreira, JJ; Teodoro, T; Pires, D; Mestre, T; Coelho, M; Rosa, MM; Sampaio, C;
PUBLICAÇÃO: 2009, FONTE: MOVEMENT DISORDERS, VOLUME: 24
INDEXADO EM: WOS
NO MEU: ORCID
505
TÍTULO: Therapeutics for Huntington's disease: a systematic review  Full Text
AUTORES: Mestre, TA; Ferreira, JJ; Coelho, M; Rosa, MM; Sampaio, C;
PUBLICAÇÃO: 2008, FONTE: 12th Congress of the European-Federation-of-Neurological-Societies in EUROPEAN JOURNAL OF NEUROLOGY, VOLUME: 15
INDEXADO EM: WOS
506
TÍTULO: A 2-year open-label study of botulinum toxin type B in botulinum toxin type A resistant/responsive cervical dystonia patients (AN072-401 EUICD)  Full Text
AUTORES: Peter Moore; Joaquim Ferreira; Eric Pappert;
PUBLICAÇÃO: 2008, FONTE: 6th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins in TOXICON, VOLUME: 51
INDEXADO EM: WOS
NO MEU: ORCID
507
TÍTULO: Is treatment of cervical dystonia patients with botulinum toxin type B affected by a previous response to a botulinum toxin type A? Analysis of a long-term open-label study (AN072-401 EU/CD)  Full Text
AUTORES: Peter Moore; Joaquim Ferreira; Terry Germanson; Eric Pappert;
PUBLICAÇÃO: 2008, FONTE: 6th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins in TOXICON, VOLUME: 51
INDEXADO EM: WOS
NO MEU: ORCID
508
TÍTULO: Botulinum toxin type A (Botox) versus botulinum toxin type B (Myobloc) in subjects with cervical dystonia: A comparison of the frequency of xerostomia and dysphagia (AN072-402 EU/CD)  Full Text
AUTORES: Eric Pappert; Terry Germanson; Peter P Moore; Joaquim Ferreira;
PUBLICAÇÃO: 2008, FONTE: 6th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins in TOXICON, VOLUME: 51
INDEXADO EM: WOS
NO MEU: ORCID
509
TÍTULO: The effects of repeated dosing of botulinum toxin type B (neurobloc (R)) in patients with cervical dystonia previously naive to botulinum toxin: An open-label extension study (AN072-402 EU/CD)  Full Text
AUTORES: Joaquim Ferreira; Peter Moore; Eric Pappert;
PUBLICAÇÃO: 2008, FONTE: 6th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins in TOXICON, VOLUME: 51
INDEXADO EM: WOS
NO MEU: ORCID
510
TÍTULO: A double-blind, randomised, placebo-controlled trial to investigate the efficacy and safety of nebicapone in levodopa-treated Parkinson's disease patients with motor fluctuations
AUTORES: Ferreira, JJ; Rascol, O; Poewe, W; Sampaio, C; Rocha, F; Nunes, T; Almeida, L; Soares da Silva, P ;
PUBLICAÇÃO: 2008, FONTE: 12th International Congress of Parkinsons Disease and Movement Disorders in MOVEMENT DISORDERS, VOLUME: 23, NÚMERO: 1
INDEXADO EM: WOS
NO MEU: ORCID
Página 51 de 57. Total de resultados: 568.

Um espaço para investigadores e suas Instituições

Links Úteis

Ajuda

© 2025 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service